Search research articles
Contact Us
Filters
Showing results (41-50 of 57) with videos related to
Page
of 6
Sort By:
Cancer
|
September 21, 2011
Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients
Alessandro Gozzetti, Alfonso Cerase, Flavia Lotti, et al.
Cancer Medicine
|
April 1, 2024
A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience
Anna Furlan, Michele Cea, Laura Pavan, et al.
Blood Cancer Journal
|
June 4, 2021
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial
Stefania Oliva, Davine Hofste Op Bruinink, Lucie Rihova, et al.
European Journal of Haematology
|
September 8, 2021
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
Paul G Richardson, Fredrik Schjesvold, Katja Weisel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2011
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial
Antonio Palumbo, Michele Cavo, Sara Bringhen, et al.
The Lancet. Haematology
|
November 26, 2020
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study
Paola Tacchetti, Lucia Pantani, Francesca Patriarca, et al.
Eclinicalmedicine
|
July 3, 2023
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial
Elena Zamagni, Stefania Oliva, Francesca Gay, et al.
European Journal of Haematology
|
January 15, 2026
Imaging in Plasma-Cell Neoplasms: Italian Experts' Recommendations
Alessandro Corso, Monia Marchetti, Monica Galli, et al.
European Journal of Haematology
|
October 30, 2021
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients
Fortunato Morabito, Elena Zamagni, Concetta Conticello, et al.
Hematological Oncology
|
February 3, 2025
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study
Enrica Antonia Martino, Daniele Derudas, Elena Rossi, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 57) with videos related to
Sort By:
Page
of 6
Cancer
|
September 21, 2011
Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients
Alessandro Gozzetti, Alfonso Cerase, Flavia Lotti, et al.
Cancer Medicine
|
April 1, 2024
A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience
Anna Furlan, Michele Cea, Laura Pavan, et al.
Blood Cancer Journal
|
June 4, 2021
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial
Stefania Oliva, Davine Hofste Op Bruinink, Lucie Rihova, et al.
European Journal of Haematology
|
September 8, 2021
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
Paul G Richardson, Fredrik Schjesvold, Katja Weisel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2011
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial
Antonio Palumbo, Michele Cavo, Sara Bringhen, et al.
The Lancet. Haematology
|
November 26, 2020
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study
Paola Tacchetti, Lucia Pantani, Francesca Patriarca, et al.
Eclinicalmedicine
|
July 3, 2023
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial
Elena Zamagni, Stefania Oliva, Francesca Gay, et al.
European Journal of Haematology
|
January 15, 2026
Imaging in Plasma-Cell Neoplasms: Italian Experts' Recommendations
Alessandro Corso, Monia Marchetti, Monica Galli, et al.
European Journal of Haematology
|
October 30, 2021
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients
Fortunato Morabito, Elena Zamagni, Concetta Conticello, et al.
Hematological Oncology
|
February 3, 2025
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study
Enrica Antonia Martino, Daniele Derudas, Elena Rossi, et al.
Page
of 6